Allez à nos transactions
Soins de la Santé

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

Services
Conseil en financement par dette ou en équité
Parties prenantes
«It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.»

Richard Marsden

CEO, Synairgen plc

Contacter l'équipe de la transaction

Geoff Nash

Geoff Nash

Directeur
Londres, Royaume-Uni
Oaklins Cavendish
Voir le profil Entrer en contact

Transactions connexes

Xeros Technology Group has completed a placing, subscription and retail offer
Machinerie Industrielle et Composantes

Xeros Technology Group has completed a placing, subscription and retail offer

Xeros Technology Group plc has raised funds to drive forward its commercialization strategy.

En apprendre plus
PCI Pal has completed an equity raise
Services Financiers | TMT

PCI Pal has completed an equity raise

PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.

En apprendre plus
CARSO Group has acquired a majority stake in AQCF Group
Placements Privés | Services de Soutien aux Entreprises | Soins de la Santé

CARSO Group has acquired a majority stake in AQCF Group

CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.

En apprendre plus